Drug Patents Expiring in 2043
1. Auvelity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11717518 | AXSOME | Bupropion dosage forms with reduced food and alcohol dosing effects |
Jan, 2043
(18 years from now) | |
| US11730706 | AXSOME | Treatment of depression in certain patient populations |
Jan, 2043
(18 years from now) | |
| US11752144 | AXSOME | Compounds and combinations thereof for treating neurological and psychiatric conditions |
Feb, 2043
(18 years from now) | |
| US11839612 | AXSOME | Compounds and combinations thereof for treating neurological and psychiatric conditions |
Mar, 2043
(18 years from now) | |
| US11844797 | AXSOME | Combination of dextromethorphan and bupropion for treating depression |
Apr, 2043
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder; Treatment of major depressive disorder by administering dextromethorphan and bupropion to a subject having moderate he...
Dosage: TABLET, EXTENDED RELEASE;ORAL
AUVELITY family patents
2. Brukinsa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11786531 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| Orphan Drug Exclusivity(ODE-276) | Nov 14, 2026 |
| New Indication(I-871) | Aug 31, 2024 |
| New Indication(I-936) | Mar 07, 2027 |
| New Indication(I-817) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-274) | Jan 19, 2030 |
| New Indication(I-874) | Sep 14, 2024 |
| Orphan Drug Exclusivity(ODE-467) | Mar 07, 2031 |
| Orphan Drug Exclusivity(ODE-371) | Aug 31, 2028 |
| Orphan Drug Exclusivity(ODE-370) | Sep 14, 2028 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) receiving a moderate cyp3a inducer
Dosage: CAPSULE;ORAL
BRUKINSA family patents
3. Igalmi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11806334 | BIOXCEL | Non-sedating dexmedetomidine treatment regimens |
Jan, 2043
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual or buccal administration in patients with severe hepatic impairment
Dosage: FILM;BUCCAL, SUBLINGUAL
IGALMI family patents